Drucker provides this illustration of the mechanism: Scientists still arent quite sure how these drugs effectively moderate every system that they touch
Moreover, a significantly greater proportion of patients with baseline prediabetes reverted to normoglycemia in the semaglutide vs
Across the full GLP-1 and obesity drug space, the post-2026 picture is a price-expansion wave led by Indian and Chinese biosimilars and by new dual or triple-agonist molecules, yet real uptake in the USA and EU will be shaped less by tariffs and more by regulatory timing, drug-device parity on pens and human-factors equivalence for AB-substitution, secondary IP and Orange Book hurdles, and payer or formulary contracting
Furthermore, the mechanism and disputes involved and therapeutic implications are also discussed in this review
Feng F, Wu J, Chi Q, Wang S, Liu W, Yang L, et al